Janux Therapeutics, Inc. (JANX)
18.88
+0.20
(+1.04%)
USD |
NASDAQ |
Aug 26, 16:00
18.70
-0.18
(-0.93%)
After-Hours: 20:00
Janux Therapeutics Enterprise Value : 191.01M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 191.01M |
| August 24, 2026 | 186.13M |
| August 21, 2026 | 112.22M |
| August 20, 2026 | 105.50M |
| August 19, 2026 | 120.16M |
| August 18, 2026 | 85.96M |
| August 17, 2026 | 43.21M |
| August 14, 2026 | 34.65M |
| August 13, 2026 | 27.32M |
| August 12, 2026 | 68.25M |
| August 11, 2026 | 59.09M |
| August 10, 2026 | 52.37M |
| August 07, 2026 | 18.16M |
| August 06, 2026 | 33.43M |
| August 05, 2026 | 27.32M |
| August 04, 2026 | 24.88M |
| August 03, 2026 | -14.21M |
| July 31, 2026 | -23.37M |
| July 30, 2026 | 1.672M |
| July 29, 2026 | -36.20M |
| July 28, 2026 | -33.75M |
| July 27, 2026 | 1.062M |
| July 24, 2026 | -13.60M |
| July 23, 2026 | 10.22M |
| July 22, 2026 | 4.115M |
| Date | Value |
|---|---|
| July 21, 2026 | 43.21M |
| July 20, 2026 | 30.38M |
| July 17, 2026 | 43.21M |
| July 16, 2026 | 17.55M |
| July 15, 2026 | 29.16M |
| July 14, 2026 | 13.89M |
| July 13, 2026 | 35.88M |
| July 10, 2026 | 51.76M |
| July 09, 2026 | 73.13M |
| July 08, 2026 | 67.64M |
| July 07, 2026 | 36.49M |
| July 06, 2026 | -8.711M |
| July 02, 2026 | -0.7709M |
| July 01, 2026 | -54.52M |
| June 30, 2026 | -11.76M |
| June 29, 2026 | -2.051M |
| June 26, 2026 | -25.48M |
| June 25, 2026 | -47.40M |
| June 24, 2026 | -43.74M |
| June 23, 2026 | -27.31M |
| June 22, 2026 | -62.00M |
| June 18, 2026 | -69.31M |
| June 17, 2026 | -73.57M |
| June 16, 2026 | -100.96M |
| June 15, 2026 | -98.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| MacroGenics, Inc. | 290.34M |
| Agenus, Inc. | 620.93M |
| Amgen, Inc. | 282.39B |
| Anika Therapeutics, Inc. | 273.23M |
| BioCryst Pharmaceuticals, Inc. | 2.993B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.97M |
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.3491 |
| Gross Profit Margin (Quarterly) | 95.49% |
| Profit Margin (Quarterly) | -214.0% |
| Earnings Yield | -8.71% |
| Normalized Earnings Yield | -8.709 |